PBAC's latest decision on Oxycodone hydrochloride: Not recommended (2015). Considered for Modified release oxycodone 5 mg strength for pain management in patients unresponsive to non-opioid analgesics.
PBAC outcome
Not recommended
2015
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2015
Submissions
1
2015 → 2015
Eligible population
Patients requiring modified release oxycodone 5 mg for pain management.
Therapy area
Pain
Line of therapy
Any
Evidence base
Cost-minimisation
Economic model
BIA only
ICER note
No economic analysis performed; this was a minor submission for a strength variation of an existing product.
Why PBAC said no
Reasons cited in the latest PSD: no pressing clinical need established for the strength; previous strength was de-listed after sponsor established no clinical need; submission did not provide financial estimates; did not establish convincing argument that clinical need now existed